Pulmonary hypertension (PH) complicates the care of patients with chronic lung disease, such as idiopathic pulmonary fibrosis (IPF), resulting in a significant increase in morbidity and mortality. Disease pathogenesis is orchestrated by unidentified myeloid-derived cells. We used murine models of PH and pulmonary fibrosis to study the role of circulating myeloid cells in disease pathogenesis and prevention. We administered clodronate liposomes to bleomycintreated wild-type mice to induce pulmonary fibrosis and PH with a resulting increase in circulating bone marrow-derived cells. We discovered that a population of C-X-C motif chemokine receptor (CXCR) 2 1 myeloid-derived suppressor cells (MDSCs), granulocytic subset (G-MDSC), is associated with severe PH in mice. Pulmonary pressures worsened despite improvement in bleomycin-induced pulmonary fibrosis. PH was attenuated by CXCR2 inhibition, with antagonist SB 225002, through decreasing G-MDSC recruitment to the lung. Molecular and cellular analysis of clinical patient samples confirmed a role for elevated MDSCs in IPF and IPF with PH. These data show that MDSCs play a key role in PH pathogenesis and that G-MDSC trafficking to the lung, through chemokine receptor CXCR2, increases development of PH in multiple murine models. Furthermore, we demonstrate pathology similar to the preclinical models in IPF with lung and blood samples from patients with PH, suggesting a potential role for CXCR2 inhibitor use in this patient population. These findings are significant, as there are currently no approved disease-specific therapies for patients with PH complicating IPF.
Annual healthcare resource utilization for patients with idiopathic pulmonary fibrosis (IPF) costs greater than $2 billion dollars (1) . Pulmonary hypertension (PH) associated with IPF is the most frequent comorbidity contributing to intensive use of hospital and emergency room services by this patient population (2, 3) . Furthermore, IPF complicated by PH is associated with significant impairment in quality-of-life, and a fourfold increase risk of death (4, 5) , compared with those patients with IPF alone. Despite the poor prognosis, there are currently no approved treatments for secondary PH. Vasodilator therapies have proven to be either unhelpful, or potentially harmful, when administered to patients with interstitial lung disease (6) (7) (8) . Thus, there is a substantial need for novel and clinically translatable pharmacologic targets in the field of pulmonary vascular biology.
Our group and others have defined a role for myeloid-derived cells in the pathogenesis of PH (9, 10) . Although the study of myeloid-derived cells in the pathobiology of vascular lung disease is still in its infancy, many groups have demonstrated strong evidence implicating leukocytes in the progression of PH (11, 12) . Although, a vast number of immune effector cells are known to be involved in aberrant pulmonary vascular injury and repair (13) (14) (15) (16) (17) , identification of a cellular intermediate orchestrating the response of these cells to inflammation and injury repair has remained elusive. Such an intermediary would prove to be a potentially efficacious drug target.
Previously, we have demonstrated the necessary role for chemokine receptors in the coordination of pathogenic vascular remodeling (18) . Chemokine receptor C-X-C motif chemokine receptor (CXCR) 2 is an attractive focus for research in the field of vascular immunobiology (19) , as it has been shown to be relevant to the pathogenesis of both PH (20) and pulmonary fibrosis (21) . We therefore investigated whether examining CXCR2 in bleomycin-induced pulmonary fibrosis can help in identifying which cellular effectors are involved in PH development. We discovered that a progenitor myeloid-cell population, myeloid-derived suppressor cells (MDSCs), is necessary for the development of experimental PH, coordinating the inflammatory milieu contributing to pulmonary vascular remodeling. Moreover, we demonstrate that, by inhibiting CXCR2, pulmonary vascular changes are attenuated, through a decrease in pulmonary trafficking of a specific MDSC subset. Together, these data support analysis of CXCR2 inhibitors in this disease entity without currently available treatments.
Methods

Mice and Clodronate Depletion
All mice were wild type, on a C57BL/6 background, with equal numbers of male and females, aged 12-16 weeks (Jackson Laboratories). Myeloid cells were stimulated through induction of chronic macrophage apoptosis (22) with 100 ml intraperitoneal liposomal clodronate 1 week before either bleomycin or chronic hypoxia exposure, and every 3 days thereafter. Clodronate liposomes and control PBS liposomes were generated as previously described (23, 24) . Animal experiments were conducted in accordance with the University of Florida (Gainesville, FL) Institutional Animal Care and Use Committee.
Bleomycin Model
Mice underwent intraperitoneal injection with 0.018 U/g bleomycin (Thermo Fisher Scientific) or vehicle twice weekly for 28 days (25, 26) . Approximately 1 week after the last injection, 33 days after initiation of bleomycin, mice were harvested for histology and hemodynamic measurements.
CXCR2 Inhibition
The selective CXCR2 antagonist SB 225002 (1.5 mg/kg; Tocris Biosciences) or vehicle (1% DMSO in PBS) was injected 
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intraperitoneally daily in mice (27) , at initiation of the bleomycin protocol. Injections occurred throughout the 33-day bleomycin protocol.
Fibrosis Evaluation
Semiquantitative lung fibrosis scoring (28) and hydroxyproline microplate assay were performed, as previously described (29) .
Hemodynamic Measurements
Invasive hemodynamic measurement was conducted, as described in previous studies (30) . In brief, right ventricular (RV) systolic pressure (mm Hg) was assessed by right heart catheterization via the right internal jugular vein in spontaneously breathing anesthetized mice. Upon completion of the measurements, blood was collected. The heart was then excised with removal of the atria, and the RV and left ventricle (LV) plus septum were isolated for measurement of the RV:LV 1 S, as previously described (31) .
Histologic Analysis
Upon harvest, the left lobe of the lung was inflated and placed in 10% formalin, as previously described (32, 33) , and the right lobes were snap frozen in liquid nitrogen for RNA and protein processing. Immunostaining was performed for a-smooth muscle actin to identify muscularized pulmonary vessels, which were then counted per high-powered field, as previously described (34) . Medial wall thickness was assessed using an established protocol (35) . In situ hybridization for CXCR2 was performed per manufacturer instructions (Advanced Cell Diagnostics).
Antibodies and Flow Cytometry
All antibodies were used according to the manufacturer's recommended protocols. Flow cytometry analyses were performed on a BD LSR II or on FACSCalibur upgraded at three lasers and eight colors (Cytek). Data were analyzed using FlowJo software (Tree Star).
Proliferation Assay
T lymphocyte proliferation assay was performed as previously described (36) .
Statistical Analysis
Statistical analysis was performed using GraphPad 
experiments). (G) CD11b
1 Gr-1 1 cells were purified from the spleens of bleomycin-and liposome-treated mice and placed in a suppression assay with purified carboxyfluorescein succinimidyl ester-stained C57BL/6 T cells at the designated ratios. Anti-CD3/CD28 beads were used to induce proliferation. Cells were harvested on Day 5 and analyzed by flow cytometry for dilution (n = 8 per mouse group experiment). Results are plotted as the mean (6SEM). *P , 0.05. Ly6 = lymphocyte antigen 6 complex.
of median and interquartile range. Data were compared using ANOVA with Bonferroni post-test for multiple comparisons or the nonparametric two-tailed Mann-Whitney test, as appropriate. Mouse data are expressed as means (6SEM). As appropriate, groups were compared by ANOVA; follow-up comparisons between groups were conducted using Student's t test. A P value of 0.05 or less was considered to be significant. Please see the data supplement for more details. Of note, portions of this article have been previously published in abstract form (37) .
Results
CXCR2 Expression Is Increased in Pulmonary Fibrosis
Mice do not naturally develop changes consistent with either PH or IPF. However, intraperitoneally administered bleomycin is a validated model for study of immune cells in pulmonary fibrosis (25) , yielding a significant and consistent degree of vascular remodeling (9, 26) . To this end, we treated wild-type C57BL/6 mice with bleomycin (0.018 U/g mouse) twice weekly for 4 weeks, followed by a 5-day observation period, before harvest and collection of tissue for analysis. To determine the pulmonary inflammatory response to an increase in the number of circulating myeloid cells (38) , we concurrently dosed mice with twice-weekly clodronate liposomes (100 mg/injection) beginning 1 week before initiation of the bleomycin treatment and continuing until the day they were killed. Using these techniques, we found that overall bone marrow cellular CXCR2 expression was increased in the clodronate liposome-treated group compared with the PBS liposome controls ( Figure 1A ). This staining correlated with an increased percentage of CXCR2 ORIGINAL RESEARCH cytometry (CD45 1 gate), from the lung of clodronate/bleomycin-treated mice ( Figures  1B and 1C ). Finally, we found an increase in whole-lung chemokine CXCL1 (the primary murine CXCR2 ligand, assessed by multiplex array; Figure 1D ) in clodronate-treated compared with PBS-treated bleomycin mice. From these data, we concluded that bleomycin and clodronate liposome exposure plausibly increases in CXCR2 1 cell trafficking to the lung.
To gain insight into effector cell distribution, we examined lung histology for localization of CXCR2. Although the chemokine receptor was only mildly expressed in bleomycin-and PBS-treated mouse sections, there was a substantial increase in the number of CXCR2
1 cells in the clodronate groups ( Figure 1E ). Strikingly, CXCR2 was expressed most strongly around pulmonary vessels. These data suggest that CXCR2-expressing cells may help coordinate pulmonary vascular inflammatory changes.
Granulocytic MDSC Trafficking Is Increased in Pulmonary Fibrosis
CXCR2 can decorate many different populations of myeloid cells, such as mature neutrophils and MDSCs. MDSCs, however, are known to play a role in not only pulmonary bleomycin-induced injury (39), but infectious/inflammatory lung disease as well (40, 41 (Figures 2A and  2B ). Of these cells, G-MDSCs, but not MoMDSCs, were increased in the bleomycinand clodronate-treated groups compared with bleomycin and PBS liposome controls ( Figure 2C ). In addition, percentage of CXCR2 1 cells was nearly 80-fold higher in G-MDSCs analyzed from mice treated with both bleomycin and clodronate liposome compared with those with bleomycin and PBS control ( Figure 2D ). These data support our hypothesis that G-MDSC accumulation within the lung is associated with increased CXCR2 expression.
G-MDSCs Accumulated in the
expression. We found that G-MDSCs from bleomycin-treated mice expressed higher levels of Arg1 and iNOS than the vehicle-treated controls (see Figure E1A in the data supplement; Figure 2E ). We next demonstrated whole-lung increase in Arg activity ( Figure 2F ) in bleomycin-clodronate-treated animals, consistent with the flow data, although nonspecific for Arg1. Finally, we confirmed isolated MDSC's immune suppressive capability in a T cell suppression assay (36) . Consistent with the enzymatic expression data, we found that MDSCs, isolated from bleomycin and clodronate liposome-treated mice spleen, functionally suppressed in vitro T cell growth ( Figure 2G ). Importantly, spleen-derived MDSCs grossly reflected the same CXCR2, Arg1, and iNOS expression pattern as that of those analyzed from the lung of treated animals ( Figures E1B and E1C) . Finally, whole-lung expression of G-MDSC-associated growth factors, such as vascular endothelial growth factor and granulocyte-colony-stimulating factor, and remodeling protein matrix metallopeptidase 9, were increased in bleomycin and clodronate liposome-treated animals, compared with appropriate controls (Figures E1D  and E1E ). Together, these data support that MDSC trafficking to the lung is increased, and that these cells retain functional immunosuppressive function.
CXCR2-Expressing G-MDSCs Are Associated with Development of PH in Absence of Pulmonary Fibrosis
Clodronate liposomes administered in models of pulmonary vascular disease (47) have variable effects (48) . Similar heterogeneity in response to clodronate treatment is described in the pulmonary fibrosis literature (23), dependent mainly upon early or late administration relative to bleomycin exposure (49) . We therefore sought to define in the bleomycin model, administered either clodronate or PBS liposomes, the PH and fibrosis phenotype. We subsequently found a large increase in PH without evidence of RV hypertrophy by RV to LV plus septal mass ratio (RV:LV 1 S; %) in mice treated with bleomycin and clodronate ( Figures 3A and 3B ). In addition, we demonstrated the same physiologic findings in chronic hypoxia (FI O 2 10% exposure, at normal atmospheric pressure, for 4 wk) induced PH ( Figures 3C  and 3D ). Pulmonary vascular pressures were increased, despite a marked decrease in parenchymal fibrosis, as assessed by fibrosis score (Figures 3E and 3F ) and measurement of collagen content ( Figure 3G ). From these findings, we conclude that, despite an improvement in pulmonary fibrosis, PH is worsened, associated with MDSC trafficking into the lung.
G-MDSC-associated Vascular Remodeling Contributes to PH
MDSCs accelerate angiogenesis, metastasis, and vascular injury and repair (50, 51) . Therefore, we examined lung sections from the clodronate-and bleomycin-treated mice for evidence of vascular remodeling by pulmonary vessel muscularization counts (52) . Though number of muscularized pulmonary vessels was similar between PBS-and clodronate liposome-treated bleomycin-exposed mice (data not shown), complete (circumferential) muscularization was nearly ninefold higher in the clodronate group. These changes were associated with an increase in medial wall thickness by greater than 10% ( Figures  4A-4C ). These data support a contributory role of G-MDSCs, expressing CXCR2, in vascular remodeling that leads to PH.
PH Associated with IPF Parallels Preclinical Studies
We next sought to understand if an MDSC population was present in patients with disease. Unlike mice, in humans, the major ligands for CXCR2 are CXCL8 (also known as IL-8) and, to a lesser extent, CXCL1 (36) . CXCL8 has previously been linked to the pathogenesis of both IPF (53) and PH (54, 55) . Therefore, we first tested plasma samples, from the National Institutes of Health Lung Tissue Research Consortium cohort, and found a significantly higher level of CXCL8 in patients with IPF and PH compared with normal control subjects or patients with IPF alone ( Figure 5A ). Levels of CXCL1 and CXCL8 in lung homogenates from the samples from patient with IPF and PH were likewise elevated compared with disease control samples from patient with IPF alone (Figures 5B and 5C ).
To explore whether patients with IPF have a greater circulating amount of G-MDSCs compared with nondisease control subjects, we prospectively recruited both normal control subjects (n = 11) and patients with a diagnosis of IPF (n = 5) from the University of Florida Pulmonary Interstitial Lung Disease Clinic (Gainesville, FL) (patient characteristics, Table E1 ). All patients that carried a diagnosis of IPF were on antifibrotic therapy (single or dual agent), though none were currently on vasodilator therapy. The peripheral blood G-MDSC population in patients with IPF was double that of normal control subjects (Figures 5D and 5E ; median and interquartile range presented), with no significant difference noted in Mo-MDSCs. These data demonstrate that the chemokine axis shown to be essential for MDSC recruitment in murine PH development is also active in patients with IPF and PH, and the specific G-MDSC population is at least elevated in patients with IPF versus healthy control subjects.
PH Is Prevented through Blockade of G-MDSC Trafficking to the Lung by CXCR2 Inhibitor
Previously, CXCR2 inhibition has been shown to be important in experimental development of both PH (19, 20) and pulmonary fibrosis (56), although a mechanism remains unspecified. Because CXCR2 1 G-MDSCs are abundant and strongly associated with PH, we hypothesized that blocking CXCR2 could prevent G-MDSC recruitment and attenuate the phenotype. Therefore, we chose to study antagonism of CXCR2 in the bleomycinclodronate model of PH through use of small molecular inhibitor, SB 225002 (daily intraperitoneal injection of 1.5 mg/kg mouse), initiated at the start of the bleomycin protocol. In mice administered SB 225002, PH was completely attenuated with resolution of pulmonary vessel muscularization to that of a normal wildtype control ( Figures 6A-6E) , with complete absence of perivascular CXCR2 expression ( Figure 6F ). CXCR1 expression was unchanged in SB 225002-treated mice compared with controls ( Figure E3A) . Consistent with the literature (21), the percentage of granulocytes in the lung, after treatment with CXCR2 inhibitor actually trended toward being higher compared with control mice, arguing that neutrophil depletion in the model does not account for the phenotype ( Figure E3B ). The lack of CXCR2 expression within the lung and the resolution of the pulmonary vascular phenotype correlated directly with decreased infiltration of G-MDSCs ( Figure 6G) , and a corresponding increase in Mo-MDSCs in mice given SB 225002, clodronate liposome, and bleomycin compared with controls. In the complete MDSC population, dualpositive Arg1 1 iNOS 1 cell populations were nearly absent in mice given SB 225002 in the bleomycin and clodronate liposome group ( Figures 6H-6J) , suggesting a comprehensive decrease in functional capability of these cells. These results demonstrate that CXCR2-mediated recruitment of G-MDSCs is necessary for development of PH.
Altogether, our data implicate G-MDSCs in the pathophysiology of PH (with the proposed mechanism summarized in Figure 7 ). Identification of these cells offers a translatable and therapeutic option to improve patient outcomes by targeting the CXCR2-positive subset of MDSCs. Though our work demonstrates utility in only prophylaxis against development of PH-as opposed to treatment of existing vasculopathy-we have demonstrated a plausible biologic mechanism for disease, laying the groundwork for performance of a clinical trial of CXCR2 inhibitors in this patient population without any current therapies.
Discussion
We present data that show that G-MDSCs expressing CXCR2 can cause PH in a model of pulmonary fibrosis, despite improvement in parenchymal lung disease. Functional and expression analysis showed that MDSCs retained immunosuppressive capabilities in these models. In addition, we demonstrate human pathology consistent with the 
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preclinical studies in patients with IPF. Finally, the murine pulmonary vascular disease is completely attenuated by antagonizing CXCR2-mediated trafficking of G-MDSCs. MDSCs evolved as a response to inflammatory stimuli, likely to minimize collateral tissue damage inflicted during the immune response to infection. However, in the setting of chronic inflammatory stimulus, this same cell population can induce a state of immune senescence, facilitating unchecked aberrant cellular proliferation (57, 58) . This malignant effect has fostered development of MDSC-inhibiting strategies, including agents directed at cell deactivation (phosphodiesterase-5 inhibitors [59] ), differentiation (all-trans retinoic acid [60] ), and multikinase inhibitors (61), which block cell development. Acting in a synergistic fashion with novel immunotherapeutic agents directed against, for example, programmed cell death protein 1 (36), CXCR2 inhibitors have shown promising results in impeding MDSC movement and function. Importantly, CXCR2 antagonists are currently being studied in patients with severe chronic obstructive pulmonary disease, having been proven to be both safe and efficacious in phase II clinical trials (62) . Our study provides solid preclinical evidence for further study of CXCR2 inhibitors in prevention, and potentially treatment, of PH associated with IPF.
Circulating MDSCs are upregulated in children with PH (63) , and in patients with IPF (64) . In patients with IPF, CD33 1
CD11b
1 cells, consistent with an MDSC expression pattern, are found within the fibrotic niche of fibrotic lung sections. Given these data and our own, it is intriguing to speculate on the use of MDSC subpopulations in identifying patients for either clinical trial enrollment, or, eventually, as informing therapeutic intervention decisions.
Although our work does not define the downstream mechanism of MDSC-mediated pulmonary vascular changes, inferences for future studies can be drawn from the demonstrated immune suppression data, specifically pertaining to arginine substrate utilization. Arginine metabolism coordinated by MDSCs through the enzymes, Arg1 and iNOS, plays many important roles in the immune suppression capability of MDSCs. Arg1 in particular leads to dysfunction of T cells through blocking the main signaling component of the T cell receptor, while simultaneously producing increased amounts of proline necessary for collagen formation (65) . Related to malignant stroma fibrotic remodeling, G-MDSCs are the primary source of Arg1 in tumor-bearing hosts, acting as the major basis of extracellular arginine depletion (66) .
A limitation of our study is that it is underpowered to detect a difference in the MDSC population within our samples from patients with IPF. In future studies with larger patient recruitment, attention will be paid to appropriate age and tobacco smoke exposure matching between healthy control subjects and patients with disease. Likewise, it is worth noting that, in the aforementioned study of MDSCs in patients with IPF, the authors described an opposite finding from our own limited report. Specifically, the group noted that, in their patients with IPF, Mo-MDSCs were elevated, whereas G-MDSCs were unchanged compared with control subjects (64) . This discrepancy in MDSC subpopulations may have been due to a number factors, including differences in flow cytometric analysis, or the fact that all of our patients with IPF were receiving concurrent antifibrotic therapies. The tyrosine kinase inhibitor family of therapeutics, of which the drug, nintedanib, is currently approved for treatment of interstitial lung disease, are known to alter maturation and function of MDSCs, resulting in multiple cytotoxic T cell changes. Given that G-MDSCs function predominantly as an antigen-specific T lymphocyte-suppressive agent, distinction between MDSC subgroup response to therapies has potentially important implications for treating patients with concurrent PH (67, 68) .
In total, other leukocytes far outnumber MDSCs within the lung, with multiple redundant regulatory pathways operating to decrease pathologic signaling (69) (70) (71) . However, little is known about these regulatory networks related to the pulmonary vasculature. Complexity of regulation highlights the potential negative outcomes of broadly directed immunobiologic targeted therapy (72) . A rigorous approach is required for use of adjuvant therapies, especially with application to disease entities outside the scope of cancer treatment. CXCR2 inhibitors are a class of drugs that has been shown to be safe in patients with advanced lung disease. Therefore, this class of drugs should be considered in clinical trials of patients with IPF at risk for development of pulmonary vascular disease. n 
